CJC-1295 & Ipamorelin Stack: Complete Research Guide 2026 - SourcePeptides.co Skip to content
Free Shipping On Every Order

CJC-1295 & Ipamorelin Stack: Complete Research Guide 2026

The CJC-1295 and Ipamorelin stack represents one of the most extensively studied growth hormone secretagogue combinations in peptide research. CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), works alongside Ipamorelin — a selective ghrelin mimetic — to stimulate pulsatile growth hormone release through two distinct but complementary receptor pathways. This dual-mechanism approach has made the combination a frequent subject of preclinical investigation, particularly in studies examining GH axis physiology, somatotroph signaling, and downstream IGF-1 dynamics.

Research interest in this peptide pair has accelerated into 2026, with laboratory teams exploring both the No DAC and DAC (Drug Affinity Complex) variants of CJC-1295 in combination protocols. Understanding how each variant interacts with Ipamorelin at the receptor level is central to designing reproducible in vitro and in vivo study models. This guide synthesizes the current preclinical evidence base, mechanistic data, and key research variables that investigators should consider when working with this stack in controlled laboratory settings.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. All referenced findings derive from preclinical and peer-reviewed studies. This material does not constitute medical advice.

🎫First order? Save 25% with code WELCOMEHOME at checkout
Research compounds discussed in this guide
Ipamorelin - 10MG
Ipamorelin — 10MG

Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$55.00 ($41.25 With Your 1st Order)
View Research Data
For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is the CJC-1295 and Ipamorelin stack in research?

The CJC-1295 and Ipamorelin stack refers to the combined use of two growth hormone secretagogues in laboratory models. CJC-1295 is a GHRH analog that stimulates somatotroph cells, while Ipamorelin is a GHSR-1a agonist (ghrelin receptor agonist). Research investigates how their dual-pathway activation produces synergistic GH pulse amplification compared to either compound alone.

What is the difference between CJC-1295 with DAC and without DAC in research?

CJC-1295 with DAC (Drug Affinity Complex) incorporates a lysine-maleimide linker that binds to serum albumin, significantly extending its half-life to approximately 6–8 days in animal models. CJC-1295 No DAC (also called Modified GRF 1-29) has a shorter half-life of roughly 30 minutes, producing more discrete GH pulses. Researchers select between the two based on whether they are studying sustained GH elevation or pulsatile release patterns.

How does Ipamorelin differ from other GHRPs in laboratory research?

Ipamorelin is distinguished in research by its high selectivity for the GHSR-1a receptor with minimal off-target activation of cortisol, prolactin, or ACTH pathways — a contrast to earlier GHRPs like GHRP-2 and GHRP-6. This selectivity makes it a cleaner model compound for isolating GH-axis effects in preclinical studies without confounding hormonal variables.

Why do researchers combine CJC-1295 with Ipamorelin rather than using either alone?

Studies suggest the combination produces synergistic GH release beyond what either peptide achieves individually. CJC-1295 amplifies the baseline GH signal through GHRH receptor activation, while Ipamorelin triggers GH release via the ghrelin receptor and also inhibits somatostatin (the primary GH suppression signal). The complementary mechanisms converge on somatotroph cells to produce significantly higher GH pulse amplitude.

What does research show about IGF-1 changes with the CJC-1295/Ipamorelin stack?

Preclinical studies have documented dose-dependent increases in serum IGF-1 following CJC-1295 administration, with the combination protocol amplifying this effect. IGF-1 elevation in animal models has been associated with downstream signaling in muscle satellite cells, hepatic protein synthesis pathways, and bone matrix formation — making IGF-1 response a key biomarker in stack research protocols.

Is CJC-1295 No DAC or CJC-1295 with DAC better for research stacking with Ipamorelin?

Research protocols differ based on study objectives. The No DAC variant is typically stacked with Ipamorelin in investigations targeting natural, pulsatile GH patterns that mimic physiological secretion. The DAC variant is studied for protocols where sustained, elevated GH levels are the research endpoint. Neither is universally “better” — the selection depends on the specific research question being investigated.

What tissues and systems have been studied in CJC-1295/Ipamorelin preclinical research?

Preclinical research has explored this stack’s effects across multiple systems, including skeletal muscle (protein synthesis and satellite cell activation), adipose tissue (lipolytic signaling), bone (density and remodeling markers), and the central nervous system (GH receptor distribution in hippocampal tissue). Researchers have also studied hepatic IGF-1 production as a downstream marker of GH axis activation.

Where can researchers source CJC-1295 and Ipamorelin for laboratory use?

Researchers can source lyophilized or nasal spray formulations of CJC-1295 and Ipamorelin from qualified research peptide suppliers. SourcePeptides.co offers both individual compounds and the pre-combined CJC-1295 No DAC + Ipamorelin stack for verified laboratory research applications.


Mechanism of Action: Dual-Pathway GH Stimulation

Understanding why the CJC-1295 and Ipamorelin combination is so frequently studied requires a clear picture of how each compound engages the GH secretory axis at the receptor level. Growth hormone release is regulated by two primary hypothalamic signals: GHRH (stimulatory) and somatostatin (inhibitory). Superimposed on this is the ghrelin/GHSR system, which provides a third regulatory input. The CJC-1295/Ipamorelin stack targets all three of these nodes simultaneously.

🎫First order? Save 25% with code WELCOMEHOME at checkout
Research compounds discussed in this guide
Ipamorelin - 10MG
Ipamorelin — 10MG

Ipamorelin - 10MG — Research-Grade Reference Material Ipamorelin - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$55.00 ($41.25 With Your 1st Order)
View Research Data
For research use only · 3rd-party tested · Free 2-5 day US shipping

CJC-1295: GHRH Receptor Agonism

CJC-1295 is a stabilized analog of endogenous GHRH(1-44). The native GHRH molecule is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other circulating proteases, limiting its research utility. CJC-1295 incorporates four amino acid substitutions that confer resistance to enzymatic degradation, dramatically extending its research-relevant activity window. Upon binding to the GHRH receptor (GHRHR) on pituitary somatotroph cells, it activates the cAMP/PKA signaling cascade, upregulating GH gene transcription and triggering calcium-mediated GH vesicle exocytosis.

The DAC variant adds a maleimide-modified lysine side chain that spontaneously forms a covalent bond with Cys-34 of serum albumin after injection. This albumin-binding mechanism extends the effective half-life to days rather than minutes, making it relevant for research models studying sustained GH axis activation. For natural pulse-focused studies, CJC-1295 No DAC — sometimes listed as Modified GRF(1-29) — preserves the discrete, episodic GH release pattern more closely resembling physiological secretion.

Ipamorelin: GHSR-1a Agonism and Somatostatin Suppression

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin mimetic that binds selectively to the growth hormone secretagogue receptor 1a (GHSR-1a). Its activation triggers intracellular IP3/DAG signaling and calcium mobilization within somatotrophs, independently stimulating GH release. Crucially, Ipamorelin’s GHSR-1a activation also appears to attenuate somatostatin tone — the primary brake on GH secretion — thereby removing inhibitory constraint at the same time CJC-1295 is pushing the accelerator.

What makes Ipamorelin particularly valuable as a research tool is its selectivity profile. Unlike GHRP-2 or GHRP-6, it demonstrates minimal activation of the ACTH/cortisol axis or prolactin secretion pathways at research-relevant concentrations. This allows investigators to attribute observed changes in GH and IGF-1 to the GH axis with greater confidence, reducing confounding hormonal signals in study data.


Synergy Data: Why the Stack Outperforms Monotherapy in Preclinical Models

The theoretical basis for synergy is well-supported by receptor pharmacology: two compounds acting through distinct, convergent pathways should produce greater-than-additive effects on a shared downstream output. In the case of CJC-1295 and Ipamorelin, animal studies have confirmed this prediction. Combination protocols in rodent models have demonstrated GH pulse amplitudes significantly greater than those produced by equivalent doses of either peptide alone — a finding that has driven continued investigation into the stack’s potential research applications.

As explored in the CJC-1295 No DAC + Ipamorelin stack research guide, the pulse amplitude synergy is particularly pronounced when the two compounds are administered simultaneously rather than sequentially, suggesting that co-occupancy of both receptor types on somatotroph cells is necessary for maximal cooperative signaling. This timing-dependent synergy is an important variable for researchers designing in vivo administration protocols.

IGF-1 serves as the most commonly measured downstream biomarker in these studies. Because hepatic IGF-1 synthesis is directly driven by GH signaling, amplified GH pulses translate proportionally into elevated serum IGF-1 in animal models. Researchers have used IGF-1 measurements as a pharmacodynamic readout to compare DAC vs. No DAC variants, different dose ratios, and varying administration frequencies within combination protocols.

CJC 1295 No DAC + Ipamorelin Nasal Spray (10MG) for research →


CJC-1295 DAC vs. No DAC: Research Protocol Implications

Feature CJC-1295 with DAC CJC-1295 No DAC (Mod GRF 1-29)
Half-life in animal models ~6–8 days ~20–30 minutes
GH release pattern Sustained, blunted pulsatility Discrete, pulsatile (physiological)
Dosing frequency in studies Once or twice weekly Multiple times daily (with Ipamorelin)
Albumin binding mechanism Yes (maleimide-DAC linker) No
Best research use case Sustained GH elevation models Pulsatile GH physiology studies
Synergy with Ipamorelin Moderate (timing less critical) High (timing-dependent)

Choose CJC-1295 No DAC + Ipamorelin if…

  • Your research model requires pulsatile, physiologically realistic GH secretion patterns
  • You are studying the acute GH pulse amplitude response to dual-receptor stimulation
  • Your protocol demands frequent dosing windows with real-time GH measurement
  • You are investigating somatostatin interplay and episodic GH regulation in rodent models

Choose CJC-1295 with DAC + Ipamorelin if…

  • Your research model requires sustained, stable GH elevation over multiple days
  • Reduced administration frequency is a practical constraint in your study design
  • You are measuring cumulative IGF-1 production over a week-long research window
  • Your study focuses on chronic anabolic signaling rather than acute GH pulsatility

CJC-1295 with DAC Nasal Spray (5MG) for research →

Ipamorelin Nasal Spray (10MG) for research →


⚡ UNLOCK 25% OFF YOUR FIRST ORDER
Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.
For research use only. No spam — unsubscribe anytime.

Downstream Research Applications

Skeletal Muscle and Protein Synthesis Research

The GH/IGF-1 axis is a primary regulator of skeletal muscle anabolism. In preclinical models, CJC-1295 administration has been associated with measurable increases in lean body mass and muscle fiber cross-sectional area, effects amplified in combination protocols. IGF-1 — the critical mediator — activates mTORC1, a master regulator of muscle protein synthesis, and promotes satellite cell proliferation and differentiation. Researchers have used the CJC-1295/Ipamorelin stack to model these pathways in aged rodent populations where GH axis decline mirrors the human aging phenotype.

Adipose Tissue and Lipolytic Signaling

GH exerts direct lipolytic effects on adipocytes through JAK2/STAT5 signaling, independent of IGF-1. Studies investigating CJC-1295 have documented reductions in adipose tissue mass in animal models, with the stack protocol accelerating this effect. The ability to study GH-driven lipolysis in isolation from IGF-1 anabolic effects has made the CJC-1295/Ipamorelin combination a useful research tool for metabolic physiology investigations. This intersects with ongoing research interest in metabolic peptides — an area where compounds like 5-Amino-1MQ’s NNMT inhibition research explores complementary mechanisms at the cellular metabolic level.

Bone Density and Remodeling Studies

Both GH and IGF-1 receptors are expressed on osteoblasts, making bone tissue a significant research target for GH secretagogue stacks. Preclinical studies have examined CJC-1295-mediated changes in bone mineral density markers, osteocalcin levels, and collagen synthesis rates. The Ipamorelin component’s additional direct GHSR-1a activation in bone-resident cells may contribute independently to remodeling activity, though this remains an active area of preclinical investigation.

Sleep Architecture and GH Pulsatility Research

A significant proportion of endogenous GH secretion occurs during slow-wave sleep, mediated partly by reduced somatostatin tone. Research has explored whether GH secretagogue administration during sleep-phase windows amplifies this natural nocturnal GH surge, with some animal data suggesting pulse augmentation during dark-phase administration in rodents. This has made sleep-timing protocols a variable of ongoing interest in CJC-1295/Ipamorelin research design, particularly when studying GH/IGF-1’s role in tissue repair and recovery during sleep.

Researchers studying recovery and tissue regeneration alongside GH axis research may also find value in reviewing the BPC-157 and TB-500 stack research guide, which examines complementary tissue repair mechanisms that operate through distinct non-GH pathways.


Nasal Spray Delivery Format in GH Secretagogue Research

The emergence of nasal spray formulations for peptide research compounds has introduced new variables for investigators to consider. Transmucosal delivery via the nasal route allows peptides to bypass first-pass hepatic metabolism and potentially access the CNS via the olfactory pathway — a route of particular interest for centrally-acting peptides like Ipamorelin, which engages GHSR-1a receptors expressed in hypothalamic tissue. For a detailed overview of formulation considerations, the lyophilized peptides guide provides context on how powder versus spray-formulated peptides differ in terms of stability, reconstitution, and bioavailability measurement for research applications.

Nasal delivery studies are still in early stages for GH secretagogues specifically, but the pharmacokinetic principles support the approach: peptides absorbed through the nasal mucosa enter systemic circulation rapidly, with Tmax values comparable to subcutaneous administration in some preclinical pharmacokinetic studies. Researchers should account for inter-subject variability in nasal mucosa permeability when designing comparative delivery-format studies.

CJC 1295 No DAC + Ipamorelin (10MG lyophilized) for research →


Research Safety Profile: What Preclinical Data Shows

From a laboratory research perspective, both CJC-1295 and Ipamorelin have demonstrated favorable preclinical safety profiles in rodent and primate models at commonly studied doses. The most frequently noted observations in animal studies include transient facial flushing responses and mild injection-site reactions — effects attributed to mast cell activation by some GHRPs, though Ipamorelin’s selectivity profile appears to minimize this compared to GHRP-6. No significant organ toxicity, carcinogenicity signals, or immune system pathology has been documented in published preclinical studies at research-relevant concentrations.

Researchers should note that sustained supraphysiological GH and IGF-1 elevation — achievable with the DAC variant at higher doses — may produce glucose metabolism changes in animal models consistent with GH’s known insulin-antagonistic effects. Monitoring fasting glucose and insulin sensitivity markers is standard practice in longer-duration preclinical protocols involving GH secretagogues. As with any research peptide, investigators should consult applicable institutional review and regulatory guidelines before commencing in vivo studies.

Researchers interested in broader regulatory context for peptide research compounds may find the FDA-approved peptides list and 2026 regulatory update a valuable resource for understanding the current research landscape.


Where These Fit in Your Research Library

The CJC-1295/Ipamorelin stack occupies a foundational position in GH axis research, and these products integrate naturally alongside complementary research tools:

CJC 1295 No DAC + Ipamorelin Nasal Spray (10MG) — primary stack formulation for research →

CJC-1295 with DAC Nasal Spray (5MG) — sustained GH elevation research model →

IGF-1 LR3 (1MG) — downstream GH axis signaling research →


Final Takeaway: What the Research Shows About CJC-1295 & Ipamorelin in 2026

The CJC-1295 and Ipamorelin stack remains one of the most mechanistically coherent peptide research combinations available in 2026. The dual-receptor approach — GHRH receptor stimulation via CJC-1295 and GHSR-1a activation with somatostatin attenuation via Ipamorelin — produces demonstrably synergistic GH pulse amplification in preclinical models. Downstream effects on IGF-1 production, skeletal muscle anabolic signaling, adipose lipolysis, and bone remodeling have been documented across a range of animal study designs, making this stack a versatile research tool for investigators studying GH axis physiology.

The choice between the DAC and No DAC variants of CJC-1295 remains the central protocol decision, with clear implications for GH pulse pattern, dosing frequency, and the specific research question being investigated. Whether the research objective is to model pulsatile physiological GH secretion or sustained GH elevation, the combination with Ipamorelin consistently demonstrates superior GH output compared to monotherapy controls in the available preclinical literature. As the research peptide field continues to evolve through 2026, the CJC-1295/Ipamorelin stack is well-positioned to remain a benchmark model system for GH axis investigation.


Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.